GLP-1RAs appear to exert dual therapeutic benefits by concurrently ameliorating neuronal and vascular pathologies through stabilization of the BRB and suppression of inflammation-driven angiogenesis
Theres a newer peptide called PDA, or pentadeca arginate, that has a very similar molecular structure as BPC-157, but instead of it being an acetate, its an arginate essentially just swapping out one amino acid for another
For people with autoimmune conditions that affect the gut, this is particularly relevant
Compounding is regulated by both FDA and state boards of pharmacy
and (b) frequency of fast foods, frozen meals, take-out foods, sweet and savory snacks, processed meats, and sugar-sweetened beverages
Adjustments are often needed based on how a patient responds and lab results